These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 22179430

  • 21. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Vivinus-Nébot M, Dainese R, Anty R, Saint-Paul MC, Nano JL, Gonthier N, Marjoux S, Frin-Mathy G, Bernard G, Hébuterne X, Tran A, Theodorou V, Piche T.
    Am J Gastroenterol; 2012 Jan; 107(1):75-81. PubMed ID: 21931380
    [Abstract] [Full Text] [Related]

  • 22. Expression of aquaporin 8 in colonic epithelium with diarrhoea-predominant irritable bowel syndrome.
    Wang JP, Hou XH.
    Chin Med J (Engl); 2007 Feb 20; 120(4):313-6. PubMed ID: 17374283
    [Abstract] [Full Text] [Related]

  • 23. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status.
    Houghton LA, Brown H, Atkinson W, Morris J, Fell C, Whorwell PJ, Lockhart S, Keevil B.
    Aliment Pharmacol Ther; 2009 Nov 01; 30(9):919-29. PubMed ID: 19691669
    [Abstract] [Full Text] [Related]

  • 24. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2.
    Valdez-Morales EE, Overington J, Guerrero-Alba R, Ochoa-Cortes F, Ibeakanma CO, Spreadbury I, Bunnett NW, Beyak M, Vanner SJ.
    Am J Gastroenterol; 2013 Oct 01; 108(10):1634-43. PubMed ID: 23958521
    [Abstract] [Full Text] [Related]

  • 25. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH.
    Aliment Pharmacol Ther; 2008 Oct 15; 28(8):994-1002. PubMed ID: 18671775
    [Abstract] [Full Text] [Related]

  • 26. Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis.
    Sikander A, Rana SV, Sharma SK, Sinha SK, Arora SK, Prasad KK, Singh K.
    Clin Chim Acta; 2010 Jan 15; 411(1-2):59-63. PubMed ID: 19833115
    [Abstract] [Full Text] [Related]

  • 27. Different segmental transit times in patients with irritable bowel syndrome and "normal" colonic transit time: is there a correlation with symptoms?
    Bouchoucha M, Devroede G, Dorval E, Faye A, Arhan P, Arsac M.
    Tech Coloproctol; 2006 Dec 15; 10(4):287-96. PubMed ID: 17115321
    [Abstract] [Full Text] [Related]

  • 28. Characterization of episodes of irritable bowel syndrome using ecological momentary assessment.
    Weinland SR, Morris CB, Hu Y, Leserman J, Bangdiwala SI, Drossman DA.
    Am J Gastroenterol; 2011 Oct 15; 106(10):1813-20. PubMed ID: 21647206
    [Abstract] [Full Text] [Related]

  • 29. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype.
    Bertiaux-Vandaële N, Youmba SB, Belmonte L, Lecleire S, Antonietti M, Gourcerol G, Leroi AM, Déchelotte P, Ménard JF, Ducrotté P, Coëffier M.
    Am J Gastroenterol; 2011 Dec 15; 106(12):2165-73. PubMed ID: 22008894
    [Abstract] [Full Text] [Related]

  • 30. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.
    Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ.
    Am J Gastroenterol; 2009 Feb 15; 104(2):404-10. PubMed ID: 19174795
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL.
    Neurogastroenterol Motil; 2011 Dec 15; 23(12):1098-104. PubMed ID: 21920001
    [Abstract] [Full Text] [Related]

  • 32. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study.
    Fukuba N, Ishihara S, Tada Y, Oshima N, Moriyama I, Yuki T, Kawashima K, Kushiyama Y, Fujishiro H, Kinoshita Y.
    Scand J Gastroenterol; 2014 Jun 15; 49(6):674-80. PubMed ID: 24646420
    [Abstract] [Full Text] [Related]

  • 33. Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models.
    Xu JR, Luo JY, Shang L, Kong WM.
    Chin J Dig Dis; 2006 Jun 15; 7(2):89-96. PubMed ID: 16643336
    [Abstract] [Full Text] [Related]

  • 34. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.
    Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR.
    Gut; 2007 Feb 15; 56(2):203-9. PubMed ID: 17005763
    [Abstract] [Full Text] [Related]

  • 35. [Changes of tight junction claudin-1,-3,-4 protein expression in the intestinal mucosa in patients with irritable bowel syndrome].
    Kong WM, Gong J, Dong L, Xu JR.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep 15; 27(9):1345-7. PubMed ID: 17884774
    [Abstract] [Full Text] [Related]

  • 36. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
    Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B, Sabaté JM.
    Neurogastroenterol Motil; 2012 Jun 15; 24(6):513-20, e246-7. PubMed ID: 22356587
    [Abstract] [Full Text] [Related]

  • 37. Visceral sensitivity and symptoms in patients with constipation- or diarrhea-predominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion.
    Caldarella MP, Milano A, Laterza F, Sacco F, Balatsinou C, Lapenna D, Pierdomenico SD, Cuccurullo F, Neri M.
    Am J Gastroenterol; 2005 Feb 15; 100(2):383-9. PubMed ID: 15667496
    [Abstract] [Full Text] [Related]

  • 38. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC, Dong L, Wang Y, Wang SH, Cao MB.
    Chin Med J (Engl); 2007 Dec 05; 120(23):2069-74. PubMed ID: 18167178
    [Abstract] [Full Text] [Related]

  • 39. Lipid-induced colonic hypersensitivity in the irritable bowel syndrome: the role of bowel habit, sex, and psychologic factors.
    Simrén M, Abrahamsson H, Björnsson ES.
    Clin Gastroenterol Hepatol; 2007 Feb 05; 5(2):201-8. PubMed ID: 17174611
    [Abstract] [Full Text] [Related]

  • 40. Motility abnormalities in irritable bowel syndrome.
    DuPont AW, Jiang ZD, Harold SA, Snyder N, Galler GW, Garcia-Torres F, DuPont HL.
    Digestion; 2014 Feb 05; 89(2):119-23. PubMed ID: 24503633
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.